Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Watson Laboratories, a subsidiary of Watson Pharmaceuticals, has submitted an abbreviated new drug application (ANDA) with the US Food and Drug Administration (FDA) to market Colesevelam HCI 625mg tablets.
Subscribe to our email newsletter
Colesevelam HCI 625mg tablets are generic version of Daiichi Sankyo’s Welchol.
Welchol is a bile acid sequestrant. It works to decrease cholesterol by increasing the removal of bile acids from the body.
In connection to Watson‘s filing of ANDA, Daiichi Sankyo and Genzyme Corporation have filed a lawsuit against Watson in the US District Court for the District of Delaware seeking to prevent Watson from commercializing its product prior to the expiration of US Patent Nos. 5,607,669 and 5,693,675.